Invivyd (IVVD) Share-based Compensation Growth (3y) (2023 - 2025)
Invivyd (IVVD) Share-based Compensation Growth (3y) (2023 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 244.08% |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn | -50.27% |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn | -0.04% |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn | 38.45% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | - |
| 10 | Invivyd | 104.14 Mn | -122.55 Mn | 16.07 Mn | -49.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.51% |
| Sep 30, 2025 | 19.73% |
| Jun 30, 2025 | -20.63% |
| Mar 31, 2025 | 122.37% |
| Dec 31, 2024 | 32.16% |
| Sep 30, 2024 | -21.74% |
| Jun 30, 2024 | 36.44% |
| Mar 31, 2024 | 109.26% |
| Dec 31, 2023 | 251.53% |